From November 6 to 8, Copenhagen hosted the annual Congress organized by the TSC Alliance, bringing together patient associations from across Europe, healthcare professionals, and representatives from the pharmaceutical industry.

Oils4Cure attended this important international meeting to share the current status of the Spectrum clinical trial.

During an oral presentation, our Director of Research presented the progress of the trial with YCJ-01, our investigational product for the treatment of refractory epilepsy associated with Tuberous Sclerosis. The response was very positive, and several European patient associations expressed interest in participating in the study and offering this therapeutic alternative to their patients.

As a result of the interest generated, it has been decided to broaden access to the trial, allowing patients from across Europe to participate through referrals from their respective associations.

Following this initiative, the first patient from Romania has already been enrolled. We hope that additional European patients will be able to travel to Spain to take part in this research.

We remain committed to advancing new therapeutic options that improve the quality of life of people living with Tuberous Sclerosis.